Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma

@article{Kong2017EfficacyOP,
  title={Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma},
  author={G. Kong and S. Grozinsky-Glasberg and M. Hofman and J. Callahan and A. Meirovitz and Ofra Maimon and D. Pattison and D. Gross and R. Hicks},
  journal={The Journal of Clinical Endocrinology & Metabolism},
  year={2017},
  volume={102},
  pages={3278–3287}
}
  • G. Kong, S. Grozinsky-Glasberg, +6 authors R. Hicks
  • Published 2017
  • Medicine
  • The Journal of Clinical Endocrinology & Metabolism
    • Purpose: Treatment options for unresectable paraganglioma (PGL)/pheochromocytoma (PCC), especially with uncontrolled secondary hypertension (HTN), are limited. Preliminary studies with peptide receptor radionuclide therapy (PRRT) suggest efficacy, but data on HTN control and survival are lacking. We assessed PRRT outcomes in such patients from two referral centers. Methods: Twenty consecutive patients (13 men; age range, 21 to 77 years) with high somatostatin receptor (SSTR) expression treated… CONTINUE READING
    View on Wolters Kluwer
    academic.oup.com
    56 Citations
    Highly Influential Citations
    3
    Background Citations
    13
    Methods Citations
    2
    Results Citations
    1
    56 Citations
    Citation Type

    Citation Type

    177Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma
    • 1
    • PDF
    Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    • 5
    • PDF
    A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation
    • 4
    • PDF
    Somatostatin receptor targeted radioligand therapy in head and neck paraganglioma.
    Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE
    • 3
    Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management
    • Oksana Hamidi
    • Medicine
    • Current opinion in endocrinology, diabetes, and obesity
    • 2019
    • 9
    Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma
    • 25
    Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
    • 14
    • Highly Influenced
    131I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with 177Lu-DOTATATE peptide receptor radionuclide therapy
    Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors
    • 21
    • PDF

    References

    SHOWING 1-10 OF 33 REFERENCES
    Peptide receptor radionuclide therapy for metastatic paragangliomas
    • 18
    Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
    • 136
    • PDF
    Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
    • F. Forrer, I. Riedweg, H. Mäcke, J. Mueller-Brand
    • Medicine
    • The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
    • 2008
    • 96
    Peptide receptor radionuclide therapy with 90Y/177Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours)
    • 40
    Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy.
    • 58
    • PDF
    Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL).
    • 59
    The Challenges of Treating Paraganglioma Patients with 177Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment Protocols
    • 15
    Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors
    • 962
    • PDF
    Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.
    • 145
    Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
    • 35
    • PDF